Home Current Issue Previous Issues Podcasts Online First ASA Practice Parameters CME For Authors Journal Info
Skip Navigation LinksHome > January 2009 - Volume 110 - Issue 1 > Practice Alert for the Perioperative Management of Patients...
Anesthesiology:
doi: 10.1097/ALN.0b013e3181928913
Special Articles

Practice Alert for the Perioperative Management of Patients with Coronary Artery Stents: A Report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters

Free Access
Article Outline
Collapse Box

Author Information

PRACTICE Alerts are consensus-based reports that address specific aspects of patient management, patient care, and patient safety.
This Practice Alert reviews published recommendations that address the perioperative management of surgical patients with recently implanted coronary artery stents. The intent of the Alert is to provide the anesthesiologist with information about (1) the increased risk of perioperative myocardial infarction and death in these patients and (2) the relation between antiplatelet therapy and acute perioperative stent thrombosis.
A major concern after successful coronary artery stent placement is the potential for acute stent thrombosis, with subsequent myocardial infarction and death.1 To prevent stent thrombosis in the nonsurgical setting, cardiologists typically recommend dual antiplatelet therapy after coronary stent placement. Dual therapy typically consists of a combination of aspirin and thienopyridine.
Premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents who are scheduled to undergo surgery increases the risk of stent thrombosis, myocardial infarction, and death. This opinion was issued as a 2007 Science Advisory by the American Heart Association (AHA), American College of Cardiology (ACC), Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association.2 This opinion is also supported by the ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery.3
Back to Top | Article Outline

When Surgery Can Be Postponed

The 2007 Science Advisory and the 2007 ACC/AHA Guidelines make similar recommendations about postponing elective surgery in patients with new coronary stents.
A. The 2007 Science Advisory recommends that elective procedures for which there is significant risk of perioperative or postoperative bleeding should be deferred until an appropriate course of thienopyridine therapy has been completed. The course of thienopyridine therapy associated with this recommendation is as follows:
Bare-metal stents: minimum of 1 month
Drug-eluting stents: 12 months after implantation if the patient is not at high risk of bleeding
B. The 2007 ACC/AHA Guidelines do not recommend elective noncardiac surgery within the following time periods after stent implantation when thienopyridine therapy or aspirin and thienopyridine therapy need to be discontinued perioperatively:
Bare-metal stents: 4–6 weeks
Drug-eluting stents: 12 months
Back to Top | Article Outline

When Surgery Cannot Be Postponed

If the course of thienopyridine therapy must be interrupted in patients with new coronary stents, both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines recommend that aspirin therapy be continued throughout the perioperative period, if possible. In addition, both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines recommend that thienopyridine therapy should be restarted as soon as possible after the procedure.
Back to Top | Article Outline

Other Considerations

Anticoagulants and antiplatelet agents with short half-lives have been suggested as a way to bridge the gap between discontinuation of antiplatelet therapy and surgery. Both the 2007 Science Advisory and the 2007 ACC/AHA Guidelines considered the current evidence for risk and benefits and jointly concluded that there is no evidence that warfarin, antithrombotics, or glycoprotein IIb/IIIa agents reduce the risk of stent thrombosis after discontinuation of oral antiplatelet agents.
In addition, the 2007 ACC/AHA Guidelines recommend that consideration should be given to continuing dual antiplatelet therapy perioperatively beyond the recommended time frame in any patient at high risk for stent thrombosis. Even after thienopyridine has been discontinued, serious consideration should be given to continuation of aspirin antiplatelet therapy perioperatively in any patient with a drug-eluting stent.
Back to Top | Article Outline

Summary of Recommendations from the 2007 Science Advisory and the 2007 ACC/AHA Guidelines

* Premature discontinuation of dual antiplatelet therapy in patients with new coronary stents is associated with an increased risk of life-threatening stent thrombosis in the perioperative period. The time period for this risk is 4–6 weeks for bare-metal stents and 12 months for drug-eluting stents.
* Recommendations about the timing of elective surgery in patients with new coronary stents are given in slightly different ways by the 2007 Science Advisory and the 2007 ACC/AHA Guidelines. The 2007 Science Advisory states that elective procedures for which there is a significant risk of perioperative or postoperative bleeding should be deferred until patients have completed an appropriate course of thienopyridine therapy. The 2007 ACC/AHA Guidelines state that elective noncardiac surgery is not recommended when thienopyridine therapy or thienopyridine and aspirin therapy needs to be continued during the perioperative period. For both recommendations, the prescribed period of thienopyridine therapy or thienopyridine and aspirin therapy is a minimum of 1 month or 4–6 weeks for bare-metal stents and 12 months for drug-eluting stents.
* If surgery cannot be deferred and thienopyridine therapy must be interrupted in patients with new coronary stents, aspirin should be continued if possible. The thienopyridine should be restarted as soon as possible after the surgical procedure.
* Consideration should be given to continuing dual antiplatelet therapy perioperatively beyond the recommended time frame in any patient at high risk for stent thrombosis. Even after thienopyridine has been discontinued, serious consideration should be given to continuation of aspirin antiplatelet therapy perioperatively in any patient with a drug-eluting stent.
Back to Top | Article Outline

References

1. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126–30

2. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813–8

3. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF: ACC/AHA guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: Executive summary. Circulation 2007; 116:1971–96

Cited By:

This article has been cited 3 time(s).

British Journal of Anaesthesia
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel
Savonitto, S; D'Urbano, M; Caracciolo, M; Barlocco, F; Mariani, G; Nichelatti, M; Klugmann, S; De Servi, S
British Journal of Anaesthesia, 104(3): 285-291.
10.1093/bja/aep373
CrossRef
Current Opinion in Critical Care
Cardiovascular problems in noncardiac surgery
London, MJ
Current Opinion in Critical Care, 15(4): 333-341.
10.1097/MCC.0b013e32832e4795
PDF (166) | CrossRef
Current Opinion in Anesthesiology
Outcomes in perioperative care
Mantz, J; Dahmani, S; Paugam-Burtz, C
Current Opinion in Anesthesiology, 23(2): 201-208.
10.1097/ACO.0b013e328336aeef
PDF (5786) | CrossRef
Back to Top | Article Outline

© 2009 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Share